首页 | 本学科首页   官方微博 | 高级检索  
检索        

越鞠丸治疗抑郁症随机双盲对照试验的病证结合研究
引用本文:张煜萱,夏友春,陈刚,王浩森.越鞠丸治疗抑郁症随机双盲对照试验的病证结合研究[J].世界科学技术-中医药现代化,2020,22(9):221-225.
作者姓名:张煜萱  夏友春  陈刚  王浩森
作者单位:南京中医药大学基础医学院转化系统生物学与神经科学研究中心中医脑病重点实验室 南京 210023;泰州市第四人民医院 泰州 225300;暨南大学中医学院脑病个性化防治跨学科研究所 广州 510632;湖北中医药大学 武汉 430065
基金项目:泰州市科技支撑(社会发展)项目(SSF20160161):越鞠丸治疗抑郁症患者康复期大脑映射区脑电变化跟踪观察及疗效相关性研究,负责人:王浩森;国家自然科学基金委面上基金项目(NO.81673625):基于PACAP-CREB信号通路的越鞠丸快速抗抑郁机制研究,负责人:陈刚;江苏省研究生科研与实践创新计划项目(KYCX19_1286),请补充课题名称,负责人:邹之璐。
摘    要:目的 检验越鞠丸的抗抑郁作用以及起效时间的快速性,研究越鞠丸对抑郁症患者中医证候改善的特点。方法 本试验收集精神科门诊就诊的抑郁症患者,将其分为2组,越鞠丸组患者使用中药越鞠丸及艾司西酞普兰安慰剂治疗,艾司西酞普兰组患者使用艾司西酞普兰及越鞠丸安慰剂进行治疗,两组患者治疗28天。使用《汉密尔顿抑郁量表(HAMD-24)》在治疗前及服药后第7、14、28天进行抗抑郁疗效评定。使用《郁证中医辨证分型量表》将患者的证候要素进行分类统计,得出5种证候因子分。结果 HAMD-24评分显示,越鞠丸组与艾司西酞普兰组服药后第7天起,与服药前相比显著下降(P < 0.05),且持续至第28天。服药28天后,越鞠丸组,肝气郁结因子分、气结痰阻因子分、气郁化火因子分显著下降(P < 0.05);艾司西酞普兰组,肝气郁结因子分、脾肾阳虚因子分、气郁化火因子分显著下降(P < 0.05)。结论 越鞠丸具有与艾司西酞普兰相当的抗抑郁的疗效。一方面,越鞠丸显著改善患者肝气郁结证、气结痰阻证、气郁化火证作用,符合中医理论预期。另一方面,越鞠丸对虚证特征明显患者的抑郁症治疗也有效,提示其具有广泛的治疗抑郁症疾病的作用。

关 键 词:病证结合  抑郁症  越鞠丸  艾司西酞普兰
收稿时间:2019/10/24 0:00:00
修稿时间:2020/12/26 0:00:00

Yueju Pill in the Treatment of Depression Combining TCM Syndrome and Disease: A Randomized Double-Blind Controlled Trial
Zhang Yuxuan,Xia Youchun,Chen Gang and Wang Haosen.Yueju Pill in the Treatment of Depression Combining TCM Syndrome and Disease: A Randomized Double-Blind Controlled Trial[J].World Science and Technology-Modernization of Traditional Chinese Medicine,2020,22(9):221-225.
Authors:Zhang Yuxuan  Xia Youchun  Chen Gang and Wang Haosen
Institution:Key Laboratory of Traditional Chinese Medicine Encephalopathy of Nanjing University of Traditional Chinese Medicine, Nanjing 210023, China,Taizhou Fourth People''s Hospital, Taizhou 225300, China,Interdisciplinary Institute for Personalized Medicine in Brain Disorders, Guangzhou 510632, China,Taizhou Fourth People''s Hospital, Taizhou 225300, China
Abstract:Objective To evaluate the effect of Yueju Pill on depression and the rapidity of its effectiveness, and to study the characteristics of Yueju Pill on the improvement of TCM syndromes in depressed patients.Methods Patients with depression were collected from psychiatric outpatient clinics and divided into two groups. The patients in the Yueju Pill group were treated with Yueju Pill and escitalopram placebo. The patients in the escitalopram group were treated with escitalopram and Yueju Pill placebo. The two groups were treated for 28 days. The efficacy was assessed by using the Hamilton Depression Rating Scale (HAMD-24) at baseline and day 7, 14, 28. The patient??s syndrome elements were categorized and counted using the Depression of TCM Syndrome Differentiation Scale.Results The HAMD-24 score showed that the Yueju group and the escitalopram group showed a significant decrease (P < 0.05) from the 7th day to the 28th day. At day 28, the Yueju Pill group, stagnation of liver qi factor, phlegm-qi stagnation factor, and qi stagnation transforming into fire factor decreased significantly (P < 0.05). The escitalopram group, stagnation of liver qi factor, stagnation of spleen deficiency factor significantly decreased (P < 0.05).Conclusion Yueju Pill has similar antidepressant effects as escitalopram. On the one hand, Yueju Pill significantly improved stagnation of liver qi, phlegm-qi stagnation, and qi stagnation transforming into fire, in line with the theoretical expectations of Chinese medicine. On the other hand, Yueju Pill is effective in the treatment of depression in patients with deficiency syndrome, suggesting that it has a wide range of treatments for depression.
Keywords:Combination of disease and syndrome  Depression  Yueju Pill  Escitalopram
本文献已被 万方数据 等数据库收录!
点击此处可从《世界科学技术-中医药现代化》浏览原始摘要信息
点击此处可从《世界科学技术-中医药现代化》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号